The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0615 ET – Merck KGaA expects its 2024 sales target to come in ...

Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck, which previously predicted 2024 sales of between 20. ... useful and valuable Life Sciences service that brings ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck made an after-tax profit of 812 million euros compared ... We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research ...

Merck, which previously predicted 2024 sales between 20.7 billion ... is the world’s largest multimedia news provider, ...

Bindra and Herzon will also remain as consultants for Merck. According to Bindra, the Modifi Bio team met with Merck in ...

NF1 affects around 1.7 million people worldwide, with about 70% being adults ... before AZ and its partner Merck were able to ...